Protein A is a cell wall protein derived from Staphylococcus aureus that exhibits unique binding properties for IgGs from a variety of mammalian species and for some IgM and IgA. It preferentially binds to the Fc region of immunoglobulins by interaction with the heavy chain.
It is conjugated to a wide variety of reporter molecules including fluorescent dyes, enzyme markers, biotin, colloidal gold, and radioactive iodine for use in immunology and other biological research without affecting the binding site. of the antibody. It is also immobilized on solid supports such as agarose beads for total purification of IgG from ascites fluid, serum, culture supernatants, and cell extract or protein of interest.
Biological products, such as therapeutic proteins, monoclonal antibodies, vaccines, and cell and gene therapy products have become increasingly important. Unlike traditional chemically synthesized drugs that act on a hydrophobic pocket of a protein to activate or inhibit a kinase pathway, biotherapeutics pharmacological action is via binding to its target or immunomodulation.
Due to the complex nature of biological products, scientists encounter multiple challenges from early drug discovery through development. For example, during identification of a clone with the desired immunogenicity that can demonstrate binding specificity to the target and subsequent modulation or elicit the desired immune response, and further during clone characterization, scale-up, and production of these products.
From discovery through manufacturing, harnessing large molecule drugs to create safe and effective therapies is complex and expensive. PerkinElmer enables scientists to develop and streamline their entire biologics workflow so they can overcome these challenges and bring consistent, high-quality, biological medicines to market faster.
